Figure 7.

In vivo protective roles of TM-25659 against weight gain and bone loss. (A) B6 WT mice were fed HFD for 7 weeks, divided into two groups (n = 6 for each group) and then injected i.p. every other day with either vehicle or TM-25659 (50 mg·kg⁻¹) for 2 weeks. Body weight was measured and expressed as mean ± SEM of six mice. (B) Twelve-week-old ob/ob mice were given either vehicle or TM-25659 (50 mg·kg⁻¹ i.p.) for 2 weeks (n = 6). Body weight was measured every 2 days. (C) Rats (n = 12) were ovariectomized (OVX) and then given oral vehicle (V), TM-25659 (TM) or alendronate (AL) every other day. AL was used as a positive control. All rats were then killed at 10 weeks after OVX. Body weight was measured and BMD was calculated using a micro-CT scanner. (D) Four-week-old osteoporotic male TH mice were given oral TM-25659 for 4 weeks. BMD was measured from each animal and expressed as mean ± SEM of six mice. *P < 0.05; **P < 0.005; ***P < 0.0005.